Chrysler Pacifica Recall Issued Due to Risk Minivan May Stall Suddenly While Driving

More than 160,000 Chrysler minivans are being recalled by federal highway safety officials after the manufacturer recognized the potential for the vehicles to experience a sudden engine stall and loss of power steering hazard, increasing the risk of a crash. 

Fiat Chrysler Automobiles (FIAT) announced a Chrysler Pacifica recall on January 12 due to a software defect that may cause the vehicle’s engine to stall, resulting in the loss of power steering and an increased auto accident risk. The recall comes following an official investigation by the National Highway Traffic Safety Administration (NHTSA).

To date, Chrysler stated no injuries or crashes have been reported in relation to the recall. However, the NHTSA has received at least 57 consumer complaints of vehicles suddenly stalling without warning while in motion. It initially opened the investigation following a November petition by the Center for Auto Safety (CAS).

Did You Know?

Ticketmaster Data Breach Impacts Millions of Customers

A massive Ticketmaster data breach exposed the names, addresses, phone numbers, credit card numbers and other personal information of more than 560 million customers, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

According to the NHTSA complaints, several customers reported the vehicles stalled unexpectedly during low speeds of travel, while idling, or during long road trips.

The NHTSA opened the investigation into the 2017 Chrysler Pacifica minivans on December 1, 2017, and, through cooperation with the manufacturer, determined that under certain circumstances the vehicles engine control module may incorrectly assess the engine’s operating status and stall the vehicle.

The recall affects about 163,000 model year 2017 Chrysler Pacifica minivans that were manufactured at the Windsor Plant in Ontario, Canada and sold throughout the United States at licensed Fiat Chrysler dealers. An estimated 7,500 impacted vehicles were distributed for sale in Canada, and another 1,000 were sold in Mexico.

According to Chrysler, owners will receive a mailed notification warning them of the potential stalling issues. They will also receive instructions on how to schedule a free repair at their local dealer. Dealers will be instructed  update to the vehicle’s engine control software in order to fix the issue.

Customers with additional questions or concerns regarding the recall are encouraged to contact FCA’s recall information center at 1-800-853-1403.

This is the second major Pacifica recall in less than a year. In August, Chrysler issued a recall of nearly 50,000 model year 2017 and 2018 Pacifica minivans due to second row seat belts unexpectedly unlatching, posing an increased crash injury risk.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Ozempic MDL Court To Evaluate Need for Gastroparesis Diagnostic Testing in GLP-1 Lawsuits
Ozempic MDL Court To Evaluate Need for Gastroparesis Diagnostic Testing in GLP-1 Lawsuits (Posted yesterday)

A federal judge has agreed to divide lawsuits over gastroparesis injuries linked to drugs like Ozempic and Mounjaro into multiple phases, examining how the condition is diagnosed and whether plaintiffs' claims are preempted by federal laws.

Adult Woman Files Similac Lawsuit Over NEC Injuries Experienced as a Newborn
Adult Woman Files Similac Lawsuit Over NEC Injuries Experienced as a Newborn (Posted 2 days ago)

Lawsuit alleges that Abbott Laboratories failed to provide families and the medical community with adequate warnings about the risks associated with it’s cow’s milk-based Similac formula, which a now adult woman indicates has left her with life-long NEC injuries.

Amended Lawsuit Over BioZorb Implant Side Effects Outlines Problems Caused By Tissue Marker Design Defects
Amended Lawsuit Over BioZorb Implant Side Effects Outlines Problems Caused By Tissue Marker Design Defects (Posted 3 days ago)

Six breast cancer patients have asked a federal judge for permission to amend a complaint filed in March 2024, which describes problems linked to the device and painful side effects experienced when the tissue marker migrated out of position or shattered inside their bodies.